H. Fibiger

H.
Christian Fibiger currently works at ImStar Therapeutics, Inc., as Director, AiVita Biomedical, Inc., as Director from 2022, and GABA Therapeutics, Inc., as Director.
Dr. Fibiger also formerly worked at MSI Methylation Sciences, Inc., as Director, iCo Therapeutics, Inc., as Director from 2008 to 2009, biOasis Technologies, Inc., as Independent Director from 2010 to 2017, Sirius Genomics, Inc., as Director, Amgen, Inc., as VP & Global Head-Neuroscience Therapeutic Area in 2007, Eli Lilly & Co., as VP-Neuroscience Discovery Research, the University of British Columbia, as Head-Neurological Sciences Division, Biovail Laboratories International SRL, as Chief Scientific Officer & Senior Vice President from 2008 to 2010, HLS Therapeutics, Inc., as Chief Scientific Officer, and MedGenesis Therapeutix, Inc., as Chief Scientific Officer from 2010 to 2017.
Dr. Fibiger received his doctorate degree in 1970 from Princeton University and undergraduate degree in 1966 from the University of Victoria.